“Bimekizumab 3-year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from Five Phase 3/3b Trials” (2024) SKIN The Journal of Cutaneous Medicine, 8(1), p. s305. doi:10.25251/skin.8.supp.305.